| 1. |
- Sanchez, Jaime S., et al.
(författare)
-
Versatile electrochemical manufacturing of mixed metal sulfide/N-doped rGO composites as bifunctional catalysts for high power rechargeable Zn–air batteries
- 2024
-
Ingår i: Journal of Materials Chemistry A. - 2050-7488 .- 2050-7496. ; 12:20, s. 11945-11959
-
Tidskriftsartikel (refereegranskat)abstract
- The development of rechargeable zinc–air batteries requires air cathodes capable of performing both the oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) with high performance and an extended operational lifespan. Here, we present a cost-effective and versatile electrochemical method for the direct assembly of such electrocatalysts, consisting of nitrogen-doped reduced graphene oxide (NrGO) and mixed transition metal sulfides (NiCoMnSx or NCMS). To this end, we use a small electric bias to electro-deposit both NrGO and NCMS directly on conductive graphene foam, resulting in a perfect porous network and two interpenetrated paths for the easy transport of electrons and ions. The NCMS/ NrGO composite shows one of the highest limiting currents reported so far for a non-noble metal catalyst. Additionally, it exhibits outstanding bifunctional performance for the ORR/OER, superior to both mixed transition metal compounds and noble metals from previous reports. Thus, it serves as a highly efficient air cathode for practical zinc–air batteries featuring high power densities (124 mW cm−2) and long catalyst durability (1560 cycles, around 260 h). We attribute the excellent performance to the synergistic effect between hetero-structured metallic sites and nitrogen dopants. Our approach can be used for preparing efficient zinc–air cathodes on conductive 3D carbon substrates with arbitrary shapes and good performance.
|
|
| 2. |
- Scutelnic, Adrian, et al.
(författare)
-
Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination.
- 2022
-
Ingår i: Annals of neurology. - : Wiley. - 1531-8249 .- 0364-5134. ; 92:4, s. 562-573
-
Tidskriftsartikel (refereegranskat)abstract
- Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality.We used data from an international prospective registry of patients with CVT after the adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable, or definite VITT-CVT cases included until January 18, 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis.Ninety-nine patients with VITT-CVT from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11 of 24 (46%), and 28 of 37 (76%) of the patients diagnosed in March, April, and from May onward, respectively, were treated in-line with VITT recommendations (p<0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 [32%] vs 29/55 [52%], adjusted odds ratio [OR]=0.43, 95% confidence interval [CI]=0.16-1.19). However, patients who received immunomodulation had lower mortality (19/65 [29%] vs 24/34 [70%], adjusted OR=0.19, 95% CI=0.06-0.58). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 [33%] vs 13/35 [37%], adjusted OR=0.70, 95% CI=0.24-2.04). Mortality was also not significantly influenced by platelet transfusion (17/27 [63%] vs 26/72 [36%], adjusted OR=2.19, 95% CI=0.74-6.54).In patients with VITT-CVT, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. ANN NEUROL 2022;92:562-573.
|
|
